利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.031 秒)

    .alpha.-pyrones for treating .alpha.-pyrone responsive states
    2.
    发明授权
    .alpha.-pyrones for treating .alpha.-pyrone responsive states 失效
    用于治疗α-吡喃酮反应状态的α-吡喃酮

    公开(公告)号：US5981496A

    公开(公告)日：1999-11-09

    申请号：US933777

    申请日：1997-09-19

    申请人： Seth Cohen ,  Zhi-Dong Jiang

    发明人： Seth Cohen ,  Zhi-Dong Jiang

    IPC分类号： A61K31/365 ,  C07D309/40 ,  A61K31/35 ,  C07D309/36

    CPC分类号： C07D309/40 ,  A61K31/365

    摘要： Novel .alpha.-pyrones are described. The .alpha.-pyrones are useful in a method for controlling .alpha.-pyrone responsive states in a mammal. The method includes administering to a mammal a therapeutically effective amount of an .alpha.-pyrone such that control of .alpha.-pyrone responsive states in a mammal occurs. .alpha.-Pyrone responsive states can be associated with undesirable cell proliferation such as bacteria or cancer. Packaged pharmaceuticals and pharmaceutical compositions including the novel .alpha.-pyrones are also described.

    摘要翻译： 描述了新型的α - 吡喃酮。 α-吡喃酮可用于控制哺乳动物中α-吡喃酮反应状态的方法。 该方法包括向哺乳动物施用治疗有效量的α-吡喃酮，使得在哺乳动物中控制α-吡喃酮反应状态发生。 α-吡喃酮响应状态可能与不期望的细胞增殖如细菌或癌症相关。 还描述了包含新型α-吡喃酮的包装药物和药物组合物。

    METALLOPROTEIN INHIBITORS
    5.
    发明申请
    METALLOPROTEIN INHIBITORS 有权
    金属蛋白酶抑制剂

    公开(公告)号：US20070117848A1

    公开(公告)日：2007-05-24

    申请号：US11554475

    申请日：2006-10-30

    申请人： David Puerta ,  Seth Cohen ,  Jana Lewis

    发明人： David Puerta ,  Seth Cohen ,  Jana Lewis

    IPC分类号： A61K31/4439 ,  A61K31/4412 ,  A61K31/405 ,  A61K31/35 ,  C07D213/63

    CPC分类号： A61K31/435 ,  A61K31/167 ,  A61K31/35 ,  C07D213/69 ,  C07D309/36 ,  C07D309/40

    摘要： The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.

    摘要翻译： 本发明涉及金属蛋白抑制剂，其包括：a。 有机取代基和与其共价结合的至少一个锌结合基团（ZBG）; 或b。 由侧链取代的ZBG，其中ZBG为式（I）：其中X为O或S，每个R 1，R 2，R 3 R 4和R 4分别是氢或有机基团。 金属蛋白抑制剂可用于预防或治疗与病理性金属蛋白酶活性相关的病理学疾病，病症或症状，和/或通过抑制所述活性而减轻。

    &agr;-pyrones for treating &agr;-pyrone responsive states
    10.
    发明授权
    &agr;-pyrones for treating &agr;-pyrone responsive states 失效
    用于治疗α-吡喃酮反应状态的α-吡喃酮

    公开(公告)号：US06469048B2

    公开(公告)日：2002-10-22

    申请号：US09364725

    申请日：1999-07-30

    申请人： Seth Cohen ,  Zhi-Dong Jiang

    发明人： Seth Cohen ,  Zhi-Dong Jiang

    IPC分类号： A61K3138

    CPC分类号： C07D309/40 ,  A61K31/365 ,  Y02A50/469 ,  Y02A50/473 ,  Y02A50/481

    摘要： Novel &agr;-pyrones are described. The &agr;-pyrones are useful in a method for controlling &agr;-pyrone responsive states in a mammal. The method includes administering to a mammal a therapeutically effective amount of an &agr;-pyrone such that control of &agr;-pyrone responsive states in a mammal occurs. &agr;-Pyrone responsive states can be associated with undesirable cell proliferation such as bacteria or cancer. Packaged pharmaceuticals and pharmaceutical compositions including the novel &agr;-pyrones are also described.

    摘要翻译： 描述了新型的α-吡喃酮。 α-吡喃酮可用于控制哺乳动物中α-吡喃酮反应状态的方法。 该方法包括向哺乳动物施用治疗有效量的α-吡喃酮，从而发生哺乳动物中α-吡喃酮反应状态的控制。 α-吡喃酮反应状态可能与不期望的细胞增殖如细菌或癌症有关。 还描述了包括新型α-吡喃酮的包装药物和药物组合物。